Dublin, Jan. 18, 2017 -- Research and Markets has announced the addition of the "Vaccine Contract Manufacturing Market, 2016 - 2026" report to their offering.
The "Vaccine Contract Manufacturing Market, 2016 - 2026" report provides an extensive study of the current market landscape of CMOs focused on vaccines.
The report assesses the key drivers that have governed the evolution of vaccine contract manufacturing market over the past several years, along with an elaborate discussion on the future trends that are likely to shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity for vaccine CMOs market over the next decade, segmented on the basis of business operations, type of expression systems and key regions.
Although big pharma players prefer to carry out most of these processes in-house, they are gradually entering into long-term partnerships with trusted contract manufacturing organizations (CMOs). On the other hand, smaller and emerging players have been known to outsource a relatively larger share of their clinical development and commercial manufacturing processes to contract manufacturing partners. The landscape is rapidly evolving. CMOs aiming to consolidate their presence in the market are expanding their service portfolios to provide end-to-end services to their clients and sponsors.
Chapter Outlines
Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high level view on the current status of the vaccine contract manufacturing market and where it is headed in the mid-long term.
Chapter 3 is a general introduction to vaccines. The chapter also includes an overview of the various expression systems used in the development of different vaccines and their related manufacturing procedures. It also provides an elaborate discussion on the need for outsourcing vaccine development and manufacturing processes. In this chapter, we have also presented a list of commonly outsourced biomanufacturing activities that we came across during the course of our research. The chapter also features a section dedicated to the challenges associated with the market.
Chapter 4 provides a comprehensive overview of the global landscape of vaccine CMOs. The chapter includes in-depth analysis based on regional distribution, scale of operation, manufacturing capabilities, type of vaccines manufactured and expression systems used.
Chapter 5 features an analysis of the trends, regulatory landscape and highlights the key players in vaccine contract manufacturing located in the US and Europe, the two leading geographies in this market. The chapter also provides a sub-market forecast for vaccine contract manufacturing segmented on the basis of expression systems used.
Chapter 6 provides details of vaccine contract manufacturing activities in China and India. It includes information on the regulatory framework, growth drivers and challenges associated with vaccine contract manufacturing in these regions. It also provides a high-level view on the production capabilities of some the key players in these emerging geographies. Additionally, a sub-market forecast for vaccine contract manufacturing segmented on the basis of expression systems used is also included in this chapter.
Chapter 7 presents an analysis of the recent developments in the vaccine contract manufacturing market. It provides a listing of the partnerships established in the recent past, along with an overview of other observed market trends, including investments and facility expansions.
Chapter 8 presents a detailed market forecast for the vaccine contract manufacturing market. Additionally, we have analyzed the future potential for specific geographies across the globe and in terms of the type of expression systems used. To account for the uncertain nature of the market, we have presented three different tracks of market evolution, namely the conservative, base and optimistic scenarios.
Chapter 9 provides a SWOT analysis capturing the key elements that are likely to influence the market's future.
Chapter 10 highlights future trends that are likely to emerge in the evolving vaccine contract manufacturing market. It includes brief discussions on important aspects such as the adoption of innovative technologies and a shift to strategic partnering. The chapter also addresses the growing market demand and how it is likely to influence the future growth and evolution of this market.
Chapter 11 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the vaccine CMOs market, based on the research and analysis described in the previous chapters.
Chapter 12 contains the transcripts of interviews conducted with representatives from renowned organizations engaged in this space.
Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 14 is an appendix that provides the list of companies and organizations mentioned in the report.
Companies Mentioned
- 3P Biopharmaceuticals
- ABL
- Acambis
- Accugenix
- Actavis
- Advanced BioScience Laboratories
- Advaxis
- Aeras
- Air Force Hospital, Guangzhou
- AJ Biologics
- Albany Molecular Research (AMRI)
- Alexion
- Algonomics
- Altaris Capital Partner
- AmbioPharm
- AnaSpec
- Aptuit
- Association for Assessment and Accreditation of Laboratory Animal Care
- Association Sportive du Golf Club Val de l'Indre
- Australian Therapeutic Goods Administration
- Avid Bioservices
- Bachem
- Batavia Biosciences
- Bavarian Nordic
- Baxter BioPharma Solutions
- BD Biosciences
- Benchmark Vaccines
- Bharat Biotech
- Bill and Melinda Gates Foundation
- BioCell Corporation
- Biocon
- BioConnections
- BioConvergence
- Biofabri
- Bioline Group of Companies
- Biological E
- BioMARC
- Biomay
- Biomedical Advanced Research and Development Authority
- BioMotiv
- Biopharmaceutical Development Program - Frederick National Laboratory for Cancer Research
- BioReliance Holdings
- BioTechnique
- Biotechnology and Biological Sciences Research Council
- Biotechnology and Biological Sciences Research Council
- Biovest International
- Boehringer Ingelheim
- Boehringer Ingelheim BioXcellence
- Bristol-Myers Squibb
- Bryllan
- CALIXAR
- Canadian Animal Health Institute
- Canadian Council on Animal Care
- Catalent
- Catalent Pharma Solutions
- Celsis International
- Centers for Disease Control and Prevention
- CEPiA Sanofi (Transgene)
- Cetus Corporation
- CEVEC Pharmaceuticals
- Charles River Laboratories International
- Chimera Biotec
- China Agricultural University
- China National Biotec Group
- Chinese Center for Disease Control and Prevention
- Cobra Biologics
- Cook Pharmica
- Council of the Chinese University of Hong Kong
- Crucell Sweden
- Cytovance Biologics
- Daiichi Sankyo
- Deltamune
- Developing Countries Vaccine Manufacturers Network
- Dr. Reddy's Laboratories
- Emergent BioSolutions
- Engineering and Physical Sciences Research Council
- Eubiologics
- Eurogentec
- European Medicines Agency
- Federation of Indian Chambers of Commerce and Industry
- Florida Biologix
- Friedrich-Loeffler-Institut
- FUJIFILM Diosynth Biotechnologies
- Gallant Custom Laboratories
- Gamma Vaccines
- Genentech
- GENEWIZ
- GlaxoSmithKline
- Global Alliance for Vaccines and Immunizations
- GNH India
- Goodwin Biotechnology
- Government of India's Universal Immunisation Programme
- Grand River Aseptic Manufacturing
- GreenPak Biotech
- Guangxi Veterinary Research Institute
- Haffkine Institute
- HALIX
- Harbin Veterinary Research Institute
- Harbin Veterinary Research Institute, China
- HK Jockey Club Charities Trust
- HLL Biotech
- Hong Kong Institute of Biotechnology
- IDT Biologika
- Immune Design
- Immune Targeting Systems
- ImmunoSite Technologies
- ImVisioN Therapeutics
- Index Ventures
- Indian Council of Medical Research
- Indian Immunologicals
- Infectious Disease Research Institute
- Innovation & Technology Commission, HKSAR Government, China
- Integrity Bio
- Intercell
- International Medica Foundation
- International Society for Pharmaceutical Engineering
- Interros Group
- Inviragen
- Irvine Pharmaceutical Services
- Jubilant HollisterStier
- KABS Pharmaceutical Services
- Kaneka Corporation
- KBI Biopharma
- LigoCyte Pharmaceuticals
- Lonza
- Magellan Biosciences
- MassBiologics
- Medicago
- Mefar Ilac (Birgi Mefar Group)
- Meridian Life Science
- Ministry of Health & Family Welfare, Government of India
- Mitsubishi Gas Chemical Company
- Mitsubishi Tanabe Pharma Corporation
- Moderna Therapeutics
- Mymetics Corporation
- National Avian Influenza Reference Laboratory
- National Heart, Lung and Blood Institute
- National Institutes of Allergy and Infectious Diseases
- Norwegian Institute of Public Health
- Novartis
- Novasep
- Novavax
- NPO Petrovax Pharm
- NTC
- OctoPlus
- Okairos
- Oncotest
- Organization for Economic Cooperation and Development
- OSO Biopharmaceuticals Manufacturing (OsoBio)
- Pacific GMP
- Panacea Biotec
- Paragon Bioservices
- PATH
- Pfenex
- Pfizer
- Pfizer CentreOne
- Pharmapak
- PharmaSynth
- Premas Biotech
- Prime European Therapeuticals
- ProBioGen
- Protagen
- PX'Therapeutics
- QuiaPEG
- RAFAGEN
- Recipharm
- Richter-Helm
- Riemser Pharma
- SAFC
- Sanofi
- Sanofi Pasteur
- Sartorius Stedim Biotech
- Serum Institute
- Shandong Zhaoxin Bio-tech Company
- Shanghai Laboratory Animal Commission
- ShangPharma
- Sigma-Aldrich
- South China Agricultural University
- Statens Serum Institut
- Stellar Biotechnologies
- Swiss State Secretariat Education, Research and Innovation
- SynCo Bio Partners
- Technology Strategy Board
- Temasek Life Sciences Ventures
- The College of Animal Science and Technology, Sichuan Agricultural University, China
- Thermo Fisher Scientific
- Tianjin CanSino Biotechnology
- UK Medicines Control Agency
- Unitech Pharma Group
- United States Food and Drug Association
- Univercells
- University of Maryland
- University of Oxford
- University of Pennsylvania
- Upperton
- Vaccibody
- Vacsera
- Valneva
- Vetter Pharma International
- VGXI
- Vibalogics
- Vivalis
- Vybion (Recombinant Protein Technologies and Products)
- Waisman Biomanufacturing
- Walter Reed Army Institute of Research - Pilot Bioproduction Facility
- Wellcome Trust
- WIL Research
- World Trade Organization
- WuXi AppTec
- Zoetis
For more information about this report visit http://www.researchandmarkets.com/research/fwlb9d/vaccine_contract
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Vaccines


Samsung Electronics Shares Jump on HBM4 Mass Production Report
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Washington Post Publisher Will Lewis Steps Down After Layoffs
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Anta Sports Expands Global Footprint With Strategic Puma Stake
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



